文献速递产科母胎医学

脊髓性肌萎缩症患者及家长对产前诊断与胎儿治疗态度的调查研究

Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy.
PubMed 文献 · Prenat Diagn · 2022-09-03

研究调查了脊髓性肌萎缩症(SMA)患者及家长对产前诊断、胎儿治疗和临床试验的态度,共114名受访者(60%为患者)。91%支持产前检测,81%认为诊断存在延迟;55%愿意参加胎儿反义寡核苷酸(ASO)I期试验,79%会选择已确立的胎儿ASO/小分子治疗;61%愿意参加胎儿基因治疗试验,87%会选择胎儿基因治疗。患者参加胎儿基因治疗试验的意愿低于家长(OR 0.31,p<0.05)。

要点

  • 91%的SMA受访者支持产前检测,81%认为自身诊断存在延迟。
  • 55%愿意参加胎儿ASO的I期试验,79%会选择已确立的胎儿ASO/小分子治疗。
  • 患者参加胎儿基因治疗试验的意愿低于家长(OR 0.31,p<0.05)。

核心结论

  • SMA患者及家长对产前检测和胎儿治疗持积极态度,基因治疗更受青睐。

研究设计与样本

  • 多学科团队设计问卷,由Cure SMA以电子方式发放给18岁以上的SMA患者及家长。

主要发现

  • 114名受访者中60%为患者,仅2例为产前诊断。
  • 91%支持产前检测,81%认为诊断存在延迟。
  • 55%愿意参加胎儿ASO的I期试验,79%会选择已确立的胎儿ASO/小分子治疗。
  • 61%愿意参加胎儿基因治疗试验,87%会选择胎儿基因治疗。
  • 患者参加胎儿基因治疗试验的意愿低于家长为孩子入组(OR 0.31,p<0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In utero SMA treatment could improve survival and neurologic outcomes. We investigated the attitudes of patients and parents with SMA regarding prenatal diagnosis, fetal therapies, and clinical trials. METHODS: A multidisciplinary team designed a questionnaire that Cure SMA electronically distributed to parents and patients (>18 years old) affected by SMA. Multivariable ordinal logistic regression was used to analyze associations between respondent characteristics and attitudes. RESULTS: Of 114 respondents (60% of whom were patients), only 2 were prenatally diagnosed. However, 91% supported prenatal testing and 81% felt there had been a delay in their diagnosis. Overall, 55% would enroll in a phase I trial for fetal antisense oligonucleotide (ASO) while 79% would choose an established fetal ASO/small molecule therapy. Overall, 61% would enroll in fetal gene therapy trials and 87% would choose fetal gene therapies. Patients were less likely to enroll in a fetal gene therapy trial than parents enrolling a child (OR 0.31, p < 0.05). Older parental age and believing there had been excessive delay in diagnosis were associated with an interest in enrolling in a fetal ASO trial (OR 1.04, 7.38, respectively, p < 0.05). CONCLUSION: In utero therapies are promising for severe genetic diseases. Patients with SMA and their parents view prenatal testing and therapies positively, with gene therapy being favored.

来源:Prenat Diagn,查看原文。版权归原作者所有。

引用

  1. Schwab ME, Shao S, Zhang L, et al. Investigating attitudes toward prenatal diagnosis and fetal therapy for spinal muscular atrophy. Prenat Diagn. 2022. PMID: 36029101. doi:10.1002/pd.6228

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。